# Biomea Fusion

Biomea Fusion is an Asset Manager based in Redwood City, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Redwood City, United States
- **Region:** North America
- **Address:** Redwood City, CA, United States
- **Founded:** 2017
- **Assets under management:** Undisclosed
- **Website:** biomeafusion.com

## Regulatory record

- **Reports private funds:** No

## About

Biomea Fusion launched in 2017 under Thomas Butler, a pharmaceutical executive who previously led rare-disease drug approvals at Zogenix. The company designs covalent small-molecule therapies for genetically defined cancers and metabolic diseases — a modality that forms permanent bonds with disease-causing proteins. The firm went public in April 2021, raising $153 million in an IPO priced at $17 per share, then added $120 million in a 2023 follow-on when shares traded near $40. The pipeline centers on icovamenib, an oral menin inhibitor. The drug targets Type 2 diabetes through a beta-cell preservation mechanism and was also tested in acute myeloid leukemia with KMT2A or NPM1 mutations. The earlier Phase II diabetes data showed HbA1c reductions of approximately 1.5% at 26 weeks, a result that drove the stock above $40. The oncology track continued in dose-expansion, but the hold bifurcated the company's valuation. Biomea's covalent library extends to a second undisclosed program, though icovamenib represents the sole clinical asset. Roughly 80 employees operated from Redwood City as of mid-2024. Ramses Erdtmann serves as COO, Steve Morris as Chief Medical Officer, and the board includes former Gilead and Celgene executives. The company reported $146 million in cash at the end of Q2 2024, giving it a runway into 2026 without requiring new financing. No parallel family office, foundation, or co-investment vehicle operates alongside the corporate entity. The firm cut discovery-stage work and narrowed spending to the clinical program after the FDA hold, per its Q3 2024 earnings call. Biomea's structural premise — irreversible binding as a therapeutic edge — separates it from reversible menin inhibitors in development at Syndax and Kura Oncology. Management's next defined milestone is a Type C meeting with the FDA in the first half of 2025, intended to resolve the hold terms or pivot the diabetes strategy entirely.

## Sectors

- Digital Health
- Healthcare Services

## People

- Thomas Butler — Chief Executive Officer & Chairman of the Board
- Ramses Erdtmann — Chief Operating Officer
- Steve Morris — Chief Medical Officer

## Questions

### What is irreversible covalent chemistry, and why does Biomea Fusion believe it matters?

Covalent inhibitors bind permanently to a target protein, disabling it until the cell degrades the drug-protein complex. This contrasts with traditional reversible drugs that cycle on and off the target, requiring sustained blood concentrations. Biomea's thesis states that covalent binding can drive deeper, more durable efficacy — but the same permanence raises toxicity questions, as off-target binding cannot be washed out. The FDA's clinical hold on icovamenib directly tests whether this mechanism creates risks that reversible competitors avoid.

### Who runs investment and capital-allocation decisions at Biomea Fusion?

As a clinical-stage public biotech, capital allocation is ultimately overseen by CEO Thomas Butler and the board of directors, which includes former Gilead and Celgene executives. There is no separate CIO or dedicated investment committee typical of a family office. Operational spending decisions flow through Butler and COO Ramses Erdtmann. The firm raised capital through an IPO and a follow-on offering managed by underwriters including J.P. Morgan, Jefferies, and Piper Sandler.

### What investment stages and deal structures is Biomea Fusion listed under in the Altss taxonomy?

Biomea Fusion is classified as an asset manager — specifically a public clinical-stage biotechnology company — not a family office or venture firm. It does not invest in external portfolio companies. All capital is deployed into internal drug development programs. The Altss taxonomy lists it under Digital Health and Healthcare Services sector tags due to its therapeutic pipeline focus.

## Related profiles

- [Lion Copper and Gold](https://altss.com/profile/lion-copper-and-gold-corp)
- [AMTD IDEA Group](https://altss.com/profile/amtd-idea-group)

---

Last updated: 2026-08-11T02:43:31.692Z

Canonical page: https://altss.com/profile/biomea-fusion-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology